Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Specimen Handling 107Biopsy 75Magnetic Resonance Spectroscopy 73pembrolizumab 56Cyclophosphamide 47fludarabine 40Nivolumab 25Carboplatin 24Cetuximab 22venetoclax 21Cisplatin 21Bevacizumab 20Radiotherapy 19atezolizumab 17X-Rays 17Ipilimumab 17fludarabine phosphate 16Fluorouracil 16Cytarabine 15Radiation 14Paclitaxel 14Leucovorin 14Irinotecan 14Gemcitabine 14durvalumab 12Temozolomide 12Pemetrexed 12CTLA-4 Antigen 12Azacitidine 12decitabine and cedazuridine drug combination 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × efineptakin alfa × 30 days × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡